Cited by 1,677Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Open access

Spranger, Stefani, Spaapen, Robbert M., Zha, Yuanyuan, Williams, Jason, Meng, Yuru, Ha, Thanh T., Gajewski, Thomas F.·2013·Science Translational Medicine

DOI 10.1126/scitranslmed.3006504PMC PMC4136707

Open this paper in CoChat — free account

Abstract

Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T(regs)), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of T(regs), in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-γ and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3006504

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137 · cited 1×
“Previous work has shown that antigen-presenting cells in the tumor microenvironment can be tolerogenic (37), and that some cytokines abundant in the tumor, such as IL-10, can inhibit dendritic cell activation and result in T cell anergy (38).”
Background
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
Background
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Although direct CCL22 production by tumor cells in other cancer types also has been suggested (34), we did not detect CCL22 mRNA expression in a series of melanoma cell lines, arguing that in the melanoma context, it is likely derived from infiltrating nontumor stromal cells (13).”
Background
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · cited 1×
“Clinical strategies to counter these immunosuppressive pathways are currently being evaluated, already with encouraging early-phase clinical trial results (10–12).”
Background
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · cited 1×
“IDO is a tryptophanmetabolizing enzyme that has been shown to contribute to peripheral immunologic tolerance (25).”
Background
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“…in mouse models include extrinsic suppression of CD8 + effector cells by CD4 + CD25 + FoxP3 + regulatory T cells (T regs ) (6), metabolic deregulation via tryptophan catabolism by indoleamine-2,3-dioxygenase (IDO) (7), and engagement of the inhibitory receptor PD-1 by the ligand PD-L1/B7-H1 (8, 9).”
Background
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · cited 2×
“It has been speculated that clinical response to antibodies targeting the PD-L1/PD-1 interaction may end up being restricted to cases in which PD-L1 expression is associated with a CD8 + T cell infiltrate and therefore is likely blunting host immunity (32).”
Background

Show all 50 references

Sorted by citations

Items 901–1,000 of 1,001

Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma
Wardhani, L. O., Matsushita, M., Iwasaki, T., Kuwamoto, S., Nonaka, D., Nagata, K., Kato, M., Kitamura, Y., & Hayashi, K. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.09.003 · Cited by 28
“PD-L1 and IDO1 were expressed by melanoma cells based on morphology but could also be expressed by some stromal cells [35].”
Background
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
Sailer, V. W., Sailer, U., Bawden, E., Zarbl, R., Wiek, C., Vogt, T. J., Dietrich, J., Loick, S., Grünwald, I., Toma, M. I., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.038 · Cited by 28
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma
de Perrot, M. E., Wu, L., Cabanero, M., Perentes, J. Y., McKee, T. D., Donahoe, L. L., Bradbury, P. A., Kohno, M., Chan, M.-L., Murakami, J., et al. (2019) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.10.122 · Cited by 29
Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 29
Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Economopoulou, P., Kladi-Skandali, A., Strati, A. D., Koytsodontis, G., Kyrodimos, E., Giotakis, E. I., Maragoudakis, P., Gagari, E., Maratou, E., Dimitriadis, G., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000646 · Cited by 29
The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer
Fan, X., Jin, J., Yan, L., Liu, L., Li, Q., & Xu, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108551 · Cited by 28
IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
Stifter, K., Krieger, J., Ruths, L., Gout, J., Mulaw, M., Lechel, A., Kleger, A., Seufferlein, T., Wagner, M., & Schirmbeck, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000692 · Cited by 28
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
Ludovini, V., Bianconi, F., Siggillino, A., Vannucci, J., Baglivo, S., Berti, V., Tofanetti, F. R., Reda, M. S., Bellezza, G., Mandarano, M., et al. (2021) · Genes · doi:10.3390/genes12020273 · Cited by 28
“In mouse melanoma models, INFγ secreted from CD8-positive T cells was reported to upregulate PD-L1 [27].”
Background
PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
Yang, Z., Peng, Y., Guo, W., Xu, J., Li, L., Tian, H., Li, R., Liu, L., Tan, F., Gao, S., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13989 · Cited by 27
Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer
Al-Saafeen, B. H., Al-Sbiei, A., Bashir, G. H., Mohamed, Y. A., Masad, R. J., Fernández-Cabezudo, M. J., & al-Ramadi, B. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017780 · Cited by 30
Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-Existing Malignancy
Mittal, R., Wagener, M. E., Breed, E. R., Liang, Z., Yoseph, B. P., Burd, E. M., Farris, A. B., Coopersmith, C. M., & Ford, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093523 · Cited by 28
An optimized peptide vaccine strategy capable of inducing multivalent CD8 + T cell responses with potent antitumor effects
Cho, H.-I., Jung, S.-H., Sohn, H., Celis, E., & Kim, T.-G. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1043504 · Cited by 27
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice
Fabian, K. P., Chi-Sabins, N., Taylor, J. L., Fecek, R. J., Weinstein, A. M., & Storkus, W. J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1290035 · Cited by 29
Caspase-1 from Human Myeloid-Derived Suppressor Cells Can Promote T Cell–Independent Tumor Proliferation
Zeng, Q., Fu, J. L., Korrer, M. J., Gorbounov, M., Murray, P. J., Pardoll, D., Masica, D. L., & Kim, Y. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0543 · Cited by 26
Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy
Omar, H. A., & Tolba, M. F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.009 · Cited by 28
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.006 · Cited by 30
Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy
Wachowska, M., Stachura, J., Tonecka, K., Fidyt, K., Braniewska, A., Sas, Z., Kotuła, I., Rygiel, T. P., Boon, L., Gołąb, J., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02528-5 · Cited by 27
Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!
Hajifathali, A., Parkhideh, S., Kazemi, M. H., Chegeni, R., Roshandel, E., & Gholizadeh, M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29769 · Cited by 26
“…alterations, and Janus kinase–signal transducer and activator of transcription‐dependent pathways resulting from EBV signaling or inflammatory cytokines such as IFN‐γ (Blank et al., 2004; Green et al., 2010, 2012; Lin, Lo, & Wu, 2010; Mathas et al., 2002; Spranger et al., 2013).”
Background
IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives
Lapenta, C., Gabriele, L., & Santini, S. M. (2020) · Vaccines · doi:10.3390/vaccines8040617 · Cited by 29
Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma
Haddad, A. F., Chen, J., Oh, T., Pereira, M. P., Joshi, R. S., & Aghi, M. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-73793-8 · Cited by 27
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies
Preddy, I., Nandoliya, K. R., Miska, J. M., & Ahmed, A. U. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.012 · Cited by 27
CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)
Nowak, J., Bentele, M., Kutle, I., Zimmermann, K., Lühmann, J. L., Steinemann, D., Kloeß, S., Koehl, U., Roßberg, W., Ahmed, A., et al. (2023) · Cancers · doi:10.3390/cancers15123169 · Cited by 27
“Another major drawback of adoptive cell therapy approaches is the upregulation of PD-L1 on target cells, which we also observed for SCC-4, SCC-25 and pHNSCC cells upon co-culture with unmodified and modified NK-92 cells (Supplementary Figure S5C) [40].”
Background
IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells
Carbotti, G., Nikpoor, A. R., Vacca, P., Gangemi, R. M. R., Giordano, C., Campelli, F., Ferrini, S., & Fabbi, M. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0608-z · Cited by 27
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential
Freeman-Keller, M., & Weber, J. S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014551747 · Cited by 26
Emerging Biomarkers as Predictors to Anti-Pd1/PD-L1 Therapies in Advanced Melanoma
Loo, K. L., & DAUD, A. I. (2016) · Immunotherapy · doi:10.2217/imt-2016-0039 · Cited by 27
Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas
Chłopik, A., Selim, M. A., Peng, Y. S., Wu, C.-L., Tell‐Martí, G., Paral, K. M., Shalin, S. C., Kraft, S., Hsu, C., Shea, C. R., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2017.12.022 · Cited by 26
Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells
Dufait, I., Pardo, J., Escors, D., Vlaeminck, Y. D., Jiang, H., Keyaerts, M., Ridder, M. D., & Breckpot, K. (2019) · Cancers · doi:10.3390/cancers11060808 · Cited by 26
PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses
Tian, H., Kang, Y., Song, X., Xu, Y., Chen, H., Gong, X., Zhang, W., Xu, Y., Xia, X., Gao, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.024 · Cited by 26
Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma
Walter, B. A., Gil, S. M., Naizhen, X., Kruhlak, M. J., Linehan, W. M., Srinivasan, R., & Merino, M. J. (2020) · Journal of Cancer · doi:10.7150/jca.35738 · Cited by 27
“Expression patterns of PD-L1 in close proximity to PD-1-positive CD8 TILs at the tumoral margin are similar to those previously reported in melanoma and some sarcomas [30].”
Result
Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy
Huang, K. C., Chiang, S., Chen, T.-W., Chen, W. T., Yang, P.-C., Ke, T., & Chao, K. S. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-79419-3 · Cited by 26
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 26
Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer
Xia, L., Wang, H., Sun, M., Yang, Y., Yao, C., He, S., Duan, H., Xia, W., Sun, R., Yao, Y., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1861-5 · Cited by 29
Gastric Cancer Cell-Derived Kynurenines Hyperactive Regulatory T Cells to Promote Chemoresistance via the IL-10/STAT3/BCL2 Signaling Pathway
Wu, D., & Wang, Z. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.0936 · Cited by 26
“Corticosteroids may enhance differentiation of Treg through TDO/KYN to promote chemotherapy resistance, which is worthy of in-depth research in the future.”
Background
Nanotechnology-integrated ferroptosis inducers: a sharp sword against tumor drug resistance
Li, C., Wu, X., Zheng, C., Xu, S., Liu, Y., Qin, J., Fan, X., Ye, Y., & Fei, W. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01350a · Cited by 26
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker
Amrane, K., Meur, C. L., Besse, B., Hémon, P., Noach, P., Pradier, O., Berthou, C., Abgral, R., & Uguen, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285895 · Cited by 25
Application and progress of nanozymes in antitumor therapy
He, G., Mei, C., Chen, C., Liu, X., Wu, J., Deng, Y., & Liao, Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130960 · Cited by 26
Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development
Sim, G. C., Chacon, J. A., Haymaker, C., Ritthipichai, K., Singh, M. P., Hwu, P., & Radvanyi, L. G. (2014) · BioDrugs · doi:10.1007/s40259-014-0097-y · Cited by 27
Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas
Arantes, D. A. C., Gonçalves, A. S., Jham, B. C., Duarte, E. C. B., de Paula, É. C., de Paula, H. M., Mendonça, E. F., & Batista, A. C. (2016) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2016.12.002 · Cited by 29
Molecular background of skin melanoma development and progression: therapeutic implications
Olbryt, M. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2019.84590 · Cited by 27
Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
Bessede, A., Peyraud, F., Moulec, S. L., Cousin, S., Cabart, M., Chomy, F., Rey, C., Lara, O., Odin, O., Nafia, I., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1928 · Cited by 27
Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model
Imran, K. M., Brock, R. M., Beitel-White, N., Powar, M., Orr, K., Aycock, K. N., Alinezhadbalalami, N., Salameh, Z. S., Eversole, P., Tintera, B., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352821 · Cited by 25
Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy
Lopresti, L., Tatangelo, V., Baldari, C. T., & Patrussi, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418527 · Cited by 27
Metabolic adaptations of brain metastasis
Parida, P. K., & Malladi, S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00848-1 · Cited by 28
Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
Ozaki, Y., Shindoh, J., Miura, Y., Nakajima, H., Oki, R., Uchiyama, M., Masuda, J., Kinowaki, K., Kondoh, C. N., Tanabe, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3785-4 · Cited by 25
Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view
Gibert‐Ramos, A., López, C., Bosch, R., Fontoura, L., Bueno, G., García‐Rojo, M., Berenguer, M., & Lejeune, M. (2019) · Histochemistry and Cell Biology · doi:10.1007/s00418-019-01802-7 · Cited by 25
NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel
Xu, J. Z., Ren, X., Guo, T., Sun, X., Chen, X., Patterson, L. H., Li, H., & Zhang, J. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105034 · Cited by 25
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
Zhang, M., Liu, K., & Wang, M. (2019) · RSC Advances · doi:10.1039/c9ra04590b · Cited by 26
Adoptive transfer of IFN-γ-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway
Yang, F., Li, Y., Zou, W., Xu, Y., Wang, H., Wang, W., & Zhao, Y. X. (2019) · Inflammation Research · doi:10.1007/s00011-019-01237-9 · Cited by 26
Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women
Meggyes, M., Nagy, D. U., & Szereday, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082536 · Cited by 25
Tumor-Infiltrating T Cells in EBV-Associated Gastric Carcinomas Exhibit High Levels of Multiple Markers of Activation, Effector Gene Expression, and Exhaustion
Salnikov, M. Y., Prusinkiewicz, M. A., Lin, S., Ghasemi, F., Cecchini, M. J., & Mymryk, J. S. (2023) · Viruses · doi:10.3390/v15010176 · Cited by 25
Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer
Wang, J., Qiu, Q., Zheng, Q., Zhao, Y., Xu, Y., Zhang, T., Wang, S., Wang, Q., Jin, Q., Ye, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207417 · Cited by 24
Anti-IL-10–mediated Enhancement of Antitumor Efficacy of a Dendritic Cell–targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons
Gordy, J. T., Luo, K., Francica, B. J., Drake, C. G., & Markham, R. B. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000212 · Cited by 25
Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer
Rosenberg, A. J., Wainwright, D. A., RADEMAKER, A. W., Galvez, C., GENET, M. D., Zhai, L., Lauing, K. L., Mulcahy, M. F., Hayes, J. P., Odell, D. D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25235 · Cited by 25
“Previous work has demonstrated that interferon-gamma (IFNɣ) secreted in the tumor microenvironment increases IDO1 expression, similar to PD-L1 [29, 32].”
BackgroundResult
PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma
Zhu, Q., Cai, M., Weng, D., Zhao, J., Pan, Q., Wang, Q., Tang, Y., He, J., Li, M., & Xia, J. (2019) · Journal of Cancer · doi:10.7150/jca.29052 · Cited by 25
“This seemingly paradoxical observation supports the new idea that the adaptive resistance is active in the tumour microenvironment [14, 27, 28].”
Background
Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model
Chitphet, K., Geary, S. M., Chan, C. H. F., Simons, A. L., Weiner, G. J., & Salem, A. K. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01108 · Cited by 25
The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context
Chia, T.-Y., Billingham, L. K., Boland, L. K., Katz, J. L., Arrieta, V. A., Shireman, J. M., Rosas, A.-L., DeLay, S. L., Zilinger, K., Geng, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1331287 · Cited by 25
“These data demonstrated that the upregulation of CXCL16 is stimulated in response to in ﬂ ammatory signals, a mechanism involved in regulating various immunosuppressive programs, including PD-L1, IDO, and Treg in ﬁ ltration (39, 41, 42).”
Background
IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
Pires, I. S., Covarrubias, G., Gomerdinger, V. F., Backlund, C. M., Bueno, E. N., Billingsley, M. M., Pryor, M. L., Shanker, A., Gordon, E., Wu, S., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02390-9 · Cited by 24
Tipping the balance: inhibitory checkpoints in intestinal homeostasis
Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 24
Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma
Chao, J. L., Korzinkin, M., Zhavoronkov, A. A., Ozerov, I. V., Walker, M. T., Higgins, K. E., Lingen, M. W., Izumchenko, E., & Savage, P. A. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100399 · Cited by 24
Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model
Nazari, H. G., Alimohammadi, M., Alimohammadi, R., Rostami, E., Bakhshandeh, M., Webster, T. J., Chalbatani, G. M., Tavakkol‐Afshari, J., & Jalali, S. A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108737 · Cited by 24
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma
Murphy, K. A., James, B. R., Guan, Y., Torry, D. S., Wilber, A. C., & Griffith, T. S. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1035849 · Cited by 24
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Tsai, K. K., & DAUD, A. I. (2015) · Drugs · doi:10.1007/s40265-015-0376-z · Cited by 24
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Ryan, J. M., Wasser, J. S., Adler, A. J., & Vella, A. T. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1152256 · Cited by 24
The possible role of CD 8+/Vα7.2+/ CD 161++ T ( MAIT ) and CD 8+/Vα7.2+/ CD 161lo T ( MAIT ‐like) cells in the pathogenesis of early‐onset pre‐eclampsia
Meggyes, M., Szanto, J., Lajko, A., Farkas, B., Várnagy, Á., Tamás, P., Hantosi, E., Mikó, É., & Szereday, L. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12805 · Cited by 25
Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity
Scherwitzl, I., Hurtado, A. M., Pierce, C. M., Vogt, S., Pampeno, C., & Meruelo, D. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.04.004 · Cited by 25
Targeting PD-1/PD-L1 in lung cancer: current perspectives
Rosell, R., González‐Cao, M., Karachaliou, N., Viteri, S., Espinosa, D. M., Teixidó, C., Ruiz, J. S., Molina‐Vila, M. Á., & Santarpía, M. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s55176 · Cited by 24
Prognostic biomarkers for immunotherapy in esophageal cancer
Xu, T., Jin, M., Wang, L., Zhang, D., Yin, Y., & Shen, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420399 · Cited by 24
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy
Coelho, R. M. L., Debets, R., & Hammerl, D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02481-w · Cited by 29
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells
Neubert, N. J., Soneson, C., Barras, D., Baumgaertner, P., Rimoldi, D., Delorenzi, M., Marraco, S. A. F., & Speiser, D. E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00326 · Cited by 23
The safety of talimogene laherparepvec for the treatment of advanced melanoma
Gangi, A., & Zager, J. S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1274729 · Cited by 23
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 28
“IDO expression specifically catabolizes tryptophan to kynurenine to inhibit dendritic cell function, block T cell proliferation, and increase MDSC and Treg infiltration([171-178]).”
Background
Utilization of combined PD-L1 expression and neutrophil-to-lymphocyte ratio prior to surgery as a prognostic factor in non-small cell lung cancer with brain metastasis
Lei, X., Huang, H., He, X., Wang, D., & Yang, Z. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.11.08 · Cited by 23
“Overexpression of PD-1 or/and PD-L1 was observed in many malignant tumors including NSCLC (5,6), breast cancer (21) and melanoma (22).”
Background
Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells
Carbotti, G., Petretto, A., Naschberger, E., Stürzl, M., Martini, S., Mingari, M. C., Filaci, G., Ferrini, S., & Fabbi, M. (2020) · Cancers · doi:10.3390/cancers12020488 · Cited by 23
“In particular, IFN-γ mediates PD-L1 expression on the tumor cells, which become resistant to the activity of Cytotoxic T-lymphocytes (CTLs) [5].”
Background
Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma
Yao, B., Wang, L., Wang, H., Bao, J., Li, Q., Yu, F., Zhu, W., Zhang, L., Li, W., Gu, Z., et al. (2021) · Aging · doi:10.18632/aging.202831 · Cited by 23
“IFN-γ can also drive the up-regulation of other negative regulatory immune checkpoint molecules such as IDO1 within the tumor microenvironment [19].”
Synthesis and biological evaluation of Al[18F]-NOTA-IPB-PDL1P as a molecular probe for PET imaging of PD-L1 positive tumors
Sun, P., Han, Y., Hu, K., Huang, S., Wang, M., Zhou, K., Fu, L., Chen, H., & Tang, G. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105682 · Cited by 23
Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
York, J., Gowrishankar, K., Micklethwaite, K. P., Palmer, S., Cunningham, A. L., & Nasr, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873701 · Cited by 22
Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors
Battaglia, N. G., Murphy, J. D., Uccello, T. P., Hughson, A. L., Gavras, N. W., Caldon, J. J., Gerber, S. A., & Lord, E. M. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100044 · Cited by 23
The prognostic and immune significance of C15orf48 in pan-cancer and its relationship with proliferation and apoptosis of thyroid carcinoma
Li, C., Tang, Y., Li, Q., Liu, H., Ma, X., Liu, H., & Shi, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131870 · Cited by 23
Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer
Yang, L., Chen, X., Lee, C., Shi, J., Lawrence, E. B., Zhang, L., Li, Y., Gao, N., Jung, S. Y., Creighton, C. J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02689-y · Cited by 24
Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
Subhadarshini, S., Sahoo, S., Debnath, S., Somarelli, J. A., & Jolly, M. K. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006766 · Cited by 28
Predictors of Tumor-Infiltrating Lymphocyte Efficacy in Melanoma
Zikich, D., Schachter, J., & Besser, M. J. (2015) · Immunotherapy · doi:10.2217/imt.15.99 · Cited by 23
A Validated T Cell Radiomics Score is Associated with Clinical Outcomes Following Multi-site SBRT and Pembrolizumab.
Korpics, M., Polley, M., Bhave, S., Redler, G., Pitroda, S., Luke, J., & Chmura, S. (2020) · International Journal of Radiation Oncology, Biology, Physics · doi:10.1016/j.ijrobp.2020.06.026 · Cited by 21
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
Ma, K., Qiao, Y., Wang, H., & Wang, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6486 · Cited by 22
“A mechanistic study of melanoma revealed that PD-L1 upregulation in the tumor microenvironment may depend on the presence of CD8 CTLs (51).”
Background
Targeting metabolism to improve CAR-T cells therapeutic efficacy
Liu, S., Zhao, Y., Gao, Y., Li, F., & Zhang, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003046 · Cited by 24
Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization
Sun, X., Nong, M.-Y., Meng, F., Xiaojuan, S., Jiang, L., Li, Z., & Zhang, P. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05138-2 · Cited by 23
Regulatory Rebound in IL-12–Treated Tumors Is Driven by Uncommitted Peripheral Regulatory T Cells
Li, Q., Virtuoso, L. P., Anderson, C. D., & Egilmez, N. K. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403078 · Cited by 22
The safety of anti PD-1 therapeutics for the treatment of melanoma
Ramelyte, E., Hogan, S. A., & Dummer, R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1248402 · Cited by 21
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
Xue, W., Brentville, V. A., Symonds, P., Cook, K., Yagita∥, H., Metheringham, R. L., & Durrant, L. G. (2016) · Oncotarget · doi:10.18632/oncotarget.13070 · Cited by 22
Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
Brockwell, N. K., Alamgeer, M., Kumar, B., Rivalland, G., John, T., & Parker, B. S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-485 · Cited by 22
“Data in multiple cancers including melanoma has demonstrated that elevated T lymphocyte infiltration and memory status in the tumor microenvironment (TME) is a predictor of patient response to ICI (7,8) and an indicator of an immune primed TME responsive to checkpoint blockade.”
Background
Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma
Zhang, C., Dang, D., Liu, C., Wang, Y., & Cong, X. (2021) · Journal of Cancer · doi:10.7150/jca.53697 · Cited by 22
“Meanwhile, Treg cells in the melanoma tumor microenvironment are driven by CD8+ T cells [54], which indicates that patients with elevated Treg cells could bear augmented CD8+ T cells simultaneously, thus having an improved survival.”
Background
Comprehensive Analysis of Prognostic Value and Immune Infiltration of NLRC4 and CASP1 in Colorectal Cancer
Li, P., Zhu, N., Wang, D., Zhou, Y., & Liu, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s353380 · Cited by 23
Icariside I – A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape
Chen, G., Huang, J., Lei, H., Wu, F., Chen, C., Song, Y., Cao, Z., Zhang, C., Zhang, C., Ma, Y., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113387 · Cited by 23
Critical role of guanylate binding protein 5 in tumor immune microenvironment and predictive value of immunotherapy response
Li, X., Song, D., Su, S., He, X., Cao, F., Yang, C., Li, K., Huang, S., Li, C., Wang, C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.984615 · Cited by 22
“We compared GBPs expression levels in four groups of patients who responded differently to ICB: progressive disease (PD), stable disease (SD), partial response (PR), and complete response (CR).”
BackgroundInfluential
Obesity Is Associated with Immunometabolic Changes in Adipose Tissue That May Drive Treatment Resistance in Breast Cancer: Immune-Metabolic Reprogramming and Novel Therapeutic Strategies
Savva, C., Copson, E., Johnson, P., Cutress, R., & Beers, S. A. (2023) · Cancers · doi:10.3390/cancers15092440 · Cited by 21
“Tumours evolve multiple mechanisms of immune escape and new therapeutic strategies to prevent this are of particular significance [98].”
Background
Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer
Ding, Y., Ding, H.-Y., Li, H., Yang, R., Huang, J., Chen, H., Wang, L.-H., Wang, Y., Hu, C., An, Y., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.06.004 · Cited by 22
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Mooradian, M. J., & Sullivan, R. J. (2023) · Cancers · doi:10.3390/cancers15164176 · Cited by 23
Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment
Zhang, L., Pakmehr, S., Shahhosseini, R., Hariri, M., Fakhrioliaei, A., Shayan, F. K., Xiang, W., & Shayan, S. K. (2023) · Medical Oncology · doi:10.1007/s12032-023-02233-0 · Cited by 24
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Su, M. Y., & Fisher, D. E. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002196 · Cited by 22
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
Elias, R., Morales, J. K., & Presley, C. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0619-0 · Cited by 22
1-Methyl-D-tryptophan Reduces Tumor CD133+ cells, Wnt/β-catenin and NF-κβp65 while Enhances Lymphocytes NF-κβ2, STAT3, and STAT4 Pathways in Murine Pancreatic Adenocarcinoma
Alahdal, M., Xing, Y., Tang, T., & Liang, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-28238-8 · Cited by 22

Authors: Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F.
Affiliations: University of Chicago (US)
Corresponding author: Spranger, Stefani
Spaapen, Robbert M.
Gajewski, Thomas F.
ORCID: Spranger, Stefani
Spaapen, Robbert M.
Zha, Yuanyuan
Williams, Jason
Gajewski, Thomas F.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-08-28
Volume: 5
Issue: 200
Pages: 200ra116-200ra116
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.3006504
PMC: PMC4136707
OpenAlex: W2136731993
Cited by: 1,677
References: 50
Citations by year: 2026: 49 · 2025: 76 · 2024: 112 · 2023: 122 · 2022: 136 · 2021: 173 · 2020: 158 · 2019: 162 · 2018: 171 · 2017: 176 · 2016: 155 · 2015: 111 · 2014: 70 · 2013: 6
FWCI: 61.01
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: melanoma, tumor microenvironment, PD-L1, indoleamine 2,3-dioxygenase, regulatory T cells, CD8+ T cells, immunosuppression, immune checkpoint, interferon-gamma, cancer immunotherapy, tumor immune evasion
MeSH terms: Animals, Humans, Interferon-gamma, Lymphocyte Activation, Melanoma, Melanoma, Experimental, Neoplasm Metastasis, Up-Regulation, CD8-Positive T-Lymphocytes, Chemokines, Xenograft Model Antitumor Assays, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks